Skye Bioscience Announces Key Findings at ObesityWeek
Skye Bioscience, Inc. (NASDAQ: SKYE), a pioneering biotechnology company, has made significant strides in addressing obesity and metabolic health disorders. Recently, they announced an exciting late-breaking oral presentation that will unveil important results from their innovative research at ObesityWeek 2025.
Presentation Details and Significance
The presentation, set for November 7, 2025, will reveal topline data from the Phase 2 proof-of-concept study known as CBeyond™, which focuses on nimacimab, a unique peripheral CB1 inhibitor antibody. With the increasing global epidemic of obesity, Skye's findings could be pivotal in evolving treatment options that improve patient outcomes.
Key Data and Findings
Recent analyses have shown that participants who received a combination of nimacimab 200 mg weekly and semaglutide experienced a significantly lower rebound weight gain compared to those who only received semaglutide. Specifically, only 18.1% of participants in the nimacimab group regained weight versus 49.8% in the semaglutide group within a 12-week post-treatment window. Such findings underscore the potential of nimacimab as an adjunct therapy for weight management.
Impact on Waist Circumference
Besides weight loss, waist circumference reductions were another critical measure of the study's success. Participants who received both nimacimab and semaglutide demonstrated a marked reduction in waist circumference, averaging -11.26 cm, which surpasses the -8.09 cm change noted in the semaglutide-only group.
Expert Insights on the Data
The Chief Medical Officer of Skye, Dr. Puneet Arora, commented on the data's implications, emphasizing the noteworthy 30% improvement in weight loss when nimacimab is combined with semaglutide. This points to nimacimab's potential as a viable treatment option for obesity, addressing the common issue of weight regain often seen with other therapies.
Future Development Plans
Punit Dhillon, the President and CEO of Skye, highlighted the company's unwavering commitment to advancing nimacimab's development, focusing on investigating the optimal dosing strategies. The company plans to conduct further studies encompassing both monotherapy and combination settings.
Overview of Skye Bioscience's Mission
Skye Bioscience is dedicated to exploring new pathways for metabolic health through innovative drugs that effectively target G-protein coupled receptors. Their ambitious strategy and ongoing clinical trials aim to translate scientific knowledge into breakthroughs that meet urgent healthcare needs.
Contact Information
For more information about Skye Bioscience or inquiries regarding their research and development, you can reach out through their investor relations:
Email: ir@skyebioscience.com
Phone: (858) 410-0266
Frequently Asked Questions
What is the focus of Skye Bioscience's research?
Skye Bioscience focuses on developing innovative therapies for obesity and metabolic health disorders through the modulation of G-protein coupled receptors.
When will Skye Bioscience present their findings?
Skye Bioscience will present their findings at ObesityWeek 2025 on November 7, 2025.
What are the key findings from the nimacimab study?
The study shows that nimacimab combined with semaglutide significantly reduces rebound weight gain compared to semaglutide alone.
Who is the presenter for the upcoming session?
Dr. Louis Aronne will present the new findings at the oral session for ObesityWeek 2025.
How can I learn more about Skye Bioscience's developments?
You can visit Skye Bioscience's official website for detailed updates or contact their investor relations directly.
